Literature DB >> 7689448

Quinolones in intracellular infections.

J C Pechère1.   

Abstract

Intracellular parasites are those which spend most of their lives within host cells. The fluoroquinolones demonstrate favourable intracellular pharmacokinetics for the treatment of intracellular infections; these agents diffuse and accumulate in the phagocytes, mainly in the cytosol, and do not associate with cellular organelles. The fluoroquinolones are generally active against Salmonella spp. in vitro, and have been used successfully in the treatment of typhoid fever, Salmonella bacteraemia in patients with AIDS, and chronic enteric carriage. Fluoroquinolone monotherapy has also been found satisfactory in the treatment of tularaemia and Mediterranean spotted fever. Quinolones, alone or in combination with other agents, have also shown promise in animal models of legionellosis and in limited clinical studies. Quinolones, particularly ciprofloxacin and ofloxacin, have notable antimycobacterial activity. Both agents have been used in combination with other antimycobacterial drugs in the treatment of infections caused by Mycobacterium tuberculosis, M. avium-intracellulare complex, rapidly growing mycobacteria and M. leprae, and deserve consideration as part of a multi-drug regimen in otherwise untreatable mycobacterial infections. Clinical data regarding fluoroquinolone monotherapy in brucellosis indicate unacceptable failure rates which preclude the use of these agents in this indication. The quinolones have some efficacy in genital chlamydial infections, but may have limitations in this indication also. In conclusion, as a result of the in vitro activity of the quinolones and their favourable pharmacokinetics, these agents are now an important part of the armamentarium against intracellular infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689448     DOI: 10.2165/00003495-199300453-00007

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  42 in total

1.  Randomized double-blind evaluation of ciprofloxacin and doxycycline for Mediterranean spotted fever.

Authors:  F Gudiol; R Pallares; J Carratala; F Bolao; J Ariza; G Rufi; P F Viladrich
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

2.  Quinolones for the treatment of brucellosis.

Authors:  R Lang; E Rubinstein
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

Review 3.  Antimicrobial therapy of rickettsial diseases.

Authors:  D Raoult; M Drancourt
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

Review 4.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 5.  Susceptibility testing of Chlamydia trachomatis: from eggs to monoclonal antibodies.

Authors:  J M Ehret; F N Judson
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  The effect of ofloxacin on the intracellular growth of Legionella pneumophila in guinea pig alveolar phagocytes.

Authors:  R B Fitzgeorge; A S Featherstone; A Baskerville
Journal:  J Antimicrob Chemother       Date:  1988-09       Impact factor: 5.790

7.  Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

8.  Fluoroquinolones in bronchopulmonary infections.

Authors:  E Rubinstein; P Potgieter
Journal:  Int J Antimicrob Agents       Date:  1993-11       Impact factor: 5.283

9.  Salmonella infections in patients with the acquired immunodeficiency syndrome.

Authors:  J L Jacobs; J W Gold; H W Murray; R B Roberts; D Armstrong
Journal:  Ann Intern Med       Date:  1985-02       Impact factor: 25.391

10.  In vitro and in vivo activities of sparfloxacin, other quinolones, and tetracyclines against Chlamydia trachomatis.

Authors:  K Nakata; H Maeda; A Fujii; S Arakawa; K Umezu; S Kamidono
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

View more
  2 in total

Review 1.  The appropriate use of quinolones.

Authors:  A Percival
Journal:  Drugs       Date:  1996       Impact factor: 9.546

2.  Invasive non-typhoidal Salmonella infections in sub-Saharan Africa: a systematic review on antimicrobial resistance and treatment.

Authors:  Bieke Tack; Jolien Vanaenrode; Jan Y Verbakel; Jaan Toelen; Jan Jacobs
Journal:  BMC Med       Date:  2020-07-17       Impact factor: 8.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.